APA (7th ed.) Citation

Ramalingam, S., & Schmid-Bindert, G. (2015). A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). Annals of oncology, 26(8), . https://doi.org/10.1093/annonc/mdv220

Chicago Style (17th ed.) Citation

Ramalingam, Suresh, and Gerald Schmid-Bindert. "A Randomized Phase II Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, in Combination with Docetaxel in Second-line Therapy of Advanced Non-small Cell Lung Cancer (GALAXY-1)." Annals of Oncology 26, no. 8 (2015). https://doi.org/10.1093/annonc/mdv220.

MLA (9th ed.) Citation

Ramalingam, Suresh, and Gerald Schmid-Bindert. "A Randomized Phase II Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, in Combination with Docetaxel in Second-line Therapy of Advanced Non-small Cell Lung Cancer (GALAXY-1)." Annals of Oncology, vol. 26, no. 8, 2015, https://doi.org/10.1093/annonc/mdv220.